Arvelle Therapeutics is responsible for the development and commercialisation of cenobamate, an investigational anti-seizure medication, in the European market.

Join Arvelle and help promote the “50 Million Steps for Epilepsy” campaign

Focused on bringing innovative solutions to patients with CNS disorders

About Cenobamate

Pipeline

International Epilepsy Day

Join our team

Media

Angelini Pharma finalizes the acquisition agreement

ONTOZRY™ (cenobamate) receives positive CHMP opinion for the adjunctive treatment of uncontrolled focal onset seizures in adults^*

Angelini Pharma acquires Arvelle Therapeutics to create a leading European innovator in Central Nervous System (CNS) and Mental Health Disorder treatments

Arvelle Announces Partnership with Durbin Across Europe

Investors + Partners

HCPs